MBF Therapeutics Inc. Company Profile, Contacts & Intelligence

Biotechnology9 employeesFounded 2008
3 contacts with email or phone data3 with email data2 with phone data
Employees
9
Company source estimate
Reachable Contacts
3
Visible contacts with email or phone data
Contacts With Email
3
3 of 4 visible contacts
Departments
1
Mapped contact coverage

MBF Therapeutics Inc. Overview

MBF Therapeutics is an immunotherapeutics company focused on animal applications of its innovative T-Max™ immunotherapeutic DNA vaccine platform. In addition, there are significant translational opportunities in human health. Our T-Max platform addresses longstanding shortcomings of traditional viral vaccine technologies based primarily on killed/inactivated (KWV) whole virus or modified live/attenuated virus vaccines (MLV/AV). Killed virus vaccines have been fairly safe but not efficacious, while MLV vaccine must replicate to generate reasonable efficacy and therefore have significant safety issues for the vaccinated animal and also the herd because of chronic carriers and viral shedding. MBFT will create safe and efficacious vaccines focused on respiratory viral diseases that cause significant negative economic and social impacts. Specifically Porcine Reproductive and Respiratory Syndrome (PRRS) considered the most economically significant disease of worldwide swine production; and African Swine Fever (ASF), a highly fatal and reportable disease that has caused billions of dollars lost due to death/cull of millions of pigs and disrupted markets and trade throughout Asia, Europe, Africa and now threatens the US with an estimated cost impact of 50 billion dollars in lost trade and containment costs. T-Max Plasmid DNA Vaccine Platform MBFT’s T-Max™ DNA vaccine platform is a proprietary process from discovery to commercialization of protective vaccines that identifies clinically relevant pathogen antigens and delivers them in proprietary formulations to stimulate durable and potent T cell immune responses. Four components differentiate the platform: 1. Novel antigen selection process to identify multiple clinically relevant antigens to create cross-protective ”universal” vaccines; 2. Cloning into proprietary plasmids containing a non-antibiotic selection system; 3. One or more immunomodulators that stimulate a strong innate immune response; and 4. CaptaVa

Industry
Biotechnology
Founded
2008
Phone Number
Available in AeroLeads
Company Email
Available in AeroLeads

MBF Therapeutics Inc. Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

3 contacts with contact data
3 with email data and 2 with phone data in the visible sample.
1 department represented
Visible contacts with email or phone data are mapped to these departments.
1 company-domain email
Visible contacts using MBF Therapeutics Inc.'s company email domain.
General
1

MBF Therapeutics Inc. People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

MBF Therapeutics Inc. Workforce Composition

Seniority breakdown across 4 visible profiles.

Individual contributor
3
Executive
1

Compare Similar Companies to MBF Therapeutics Inc.

Explore companies in related markets and compare their industry and employee estimates.

Company Industry / match Employee estimate Page
Proteon Pharmaceuticals Biotechnology Research 81 View company
Distribuidora Medivet Wholesale 12 View company
Agro Salud Animal Pharmaceutical Manufacturing 11 View company
Accencio® Software Development 8 View company
Opsidio, LLC Biotechnology 4 View company
Emmyon, Inc. Biotechnology Research 3 View company
ReEngage Therapeutics Biotechnology Research 3 View company
Beluga Animal Health Pharmaceutical Manufacturing 2 View company
Panorama Medicine Biotechnology Research 1 View company
JDP THERAPEUTICS INC - (Acquired) Pharmaceutical Manufacturing Not listed View company